Female Sexual Dysfunction - Pipeline Review, H1 2018

  • ID: 4576113
  • Drug Pipelines
  • 67 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Callitas Therapeutics Inc
  • Dare Bioscience Inc
  • Emotional Brain BV
  • EndoCeutics Inc
  • GlaxoSmithKline Plc
  • M et P Pharma AG
  • MORE
Female Sexual Dysfunction - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction - Pipeline Review, H1 2018, provides an overview of the Female Sexual Dysfunction (Women's Health) pipeline landscape.

Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.

Report Highlights:

This latest pipeline guide Female Sexual Dysfunction - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 1, 5, 2 and 1 respectively.

Female Sexual Dysfunction (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Female Sexual Dysfunction (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Women's Health)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Callitas Therapeutics Inc
  • Dare Bioscience Inc
  • Emotional Brain BV
  • EndoCeutics Inc
  • GlaxoSmithKline Plc
  • M et P Pharma AG
  • MORE
Introduction

Report Coverage

Female Sexual Dysfunction - Overview

Female Sexual Dysfunction - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Female Sexual Dysfunction - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Female Sexual Dysfunction - Companies Involved in Therapeutics Development

Callitas Therapeutics Inc

Dare Bioscience Inc

Emotional Brain BV

EndoCeutics Inc

Fabre-Kramer Pharmaceuticals Inc

GlaxoSmithKline Plc

Kuhnil Pharmaceutical Co Ltd

M et P Pharma AG

Palatin Technologies Inc

Pivot Pharmaceuticals Inc

Re-Pharm Ltd

S1 Biopharma Inc

Female Sexual Dysfunction - Drug Profiles

(buspirone hydrochloride + testosterone) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(sildenafil citrate + testosterone) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AB-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bremelanotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FKW-00GA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gepirone hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KI-1120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prasterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVT-011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S1B-3006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S1B-307 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SIP-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Sexual Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Estrogen Receptor for Female Sexual Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TBS-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Female Sexual Dysfunction - Dormant Projects

Female Sexual Dysfunction - Discontinued Products

Female Sexual Dysfunction - Product Development Milestones

Featured News & Press Releases

May 09, 2018: AMAG Pharmaceuticals Commends CMS for Clarifying Part D Coverage of Treatments for Moderate to Severe Dyspareunia Due to Menopause

Apr 05, 2018: Acerus to Present TEFINA at the Next CHINABIO Partnering Forum

Mar 26, 2018: AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women

Jan 09, 2018: Emotional Brain FSIAD Product Lybridos shows High Efficacy and Safety in Phase 2B Trials

Jan 09, 2018: Emotional Brain's FSIAD Product Lybrido shows High Efficacy and Safety in Phase 2B Trials

Jan 08, 2018: Callitas Health Provides Update on Extrinsa

Oct 11, 2017: Callitas Announces Positive FDA Response to Extrinsa Pre-IND Submission

Jul 24, 2017: AMAG Pharmaceuticals Launches Intrarosa (prasterone) in the U.S. - a Novel Product to Treat Moderate to Severe Dyspareunia Due to Menopause

Jul 18, 2017: M Pharmaceutical Plans to Submit Extrinsa PIND Meeting Request Letter and Package to US FDA

Jul 14, 2017: M Pharmaceutical Provides Update on Extrinsa

Jun 06, 2017: M Pharmaceutical Receives USPTO Trademark Protection for Extrinsa for the Treatment of Female Sexual Dysfunction

Mar 20, 2017: Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women

Mar 20, 2017: Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women

Feb 27, 2017: AMAG and Palatin Announce Rekynda Data Presentations at the International Society for the Study of Women’s Sexual Health Annual Meeting

Nov 01, 2016: Bremelanotide Meets Co-Primary Endpoints in Palatins Phase 3 Trials for Hypoactive Sexual Desire Disorder

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Female Sexual Dysfunction, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Female Sexual Dysfunction - Pipeline by Callitas Therapeutics Inc, H1 2018

Female Sexual Dysfunction - Pipeline by Dare Bioscience Inc, H1 2018

Female Sexual Dysfunction - Pipeline by Emotional Brain BV, H1 2018

Female Sexual Dysfunction - Pipeline by EndoCeutics Inc, H1 2018

Female Sexual Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2018

Female Sexual Dysfunction - Pipeline by GlaxoSmithKline Plc, H1 2018

Female Sexual Dysfunction - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2018

Female Sexual Dysfunction - Pipeline by M et P Pharma AG, H1 2018

Female Sexual Dysfunction - Pipeline by Palatin Technologies Inc, H1 2018

Female Sexual Dysfunction - Pipeline by Pivot Pharmaceuticals Inc, H1 2018

Female Sexual Dysfunction - Pipeline by Re-Pharm Ltd, H1 2018

Female Sexual Dysfunction - Pipeline by S1 Biopharma Inc, H1 2018

Female Sexual Dysfunction - Dormant Projects, H1 2018

Female Sexual Dysfunction - Dormant Projects, H1 2018 (Contd..1), H1 2018

Female Sexual Dysfunction - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Female Sexual Dysfunction, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Callitas Therapeutics Inc
  • Dare Bioscience Inc
  • Emotional Brain BV
  • EndoCeutics Inc
  • Fabre-Kramer Pharmaceuticals Inc
  • GlaxoSmithKline Plc
  • Kuhnil Pharmaceutical Co Ltd
  • M et P Pharma AG
  • Palatin Technologies Inc
  • Pivot Pharmaceuticals Inc
  • Re-Pharm Ltd
  • S1 Biopharma Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll